Qiagen NV
NYSE:QGEN

Watchlist Manager
Qiagen NV Logo
Qiagen NV
NYSE:QGEN
Watchlist
Price: 42.78 USD 1.06% Market Closed
Market Cap: 9.5B USD
Have any thoughts about
Qiagen NV?
Write Note

Intrinsic Value

The intrinsic value of one QGEN stock under the Base Case scenario is 40.9 USD. Compared to the current market price of 42.78 USD, Qiagen NV is Overvalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

QGEN Intrinsic Value
40.9 USD
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Qiagen NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for QGEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about QGEN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Qiagen NV

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Qiagen NV

Provide an overview of the primary business activities
of Qiagen NV.

What unique competitive advantages
does Qiagen NV hold over its rivals?

What risks and challenges
does Qiagen NV face in the near future?

Has there been any significant insider trading activity
in Qiagen NV recently?

Summarize the latest earnings call
of Qiagen NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Qiagen NV.

Provide P/S
for Qiagen NV.

Provide P/E
for Qiagen NV.

Provide P/OCF
for Qiagen NV.

Provide P/FCFE
for Qiagen NV.

Provide P/B
for Qiagen NV.

Provide EV/S
for Qiagen NV.

Provide EV/GP
for Qiagen NV.

Provide EV/EBITDA
for Qiagen NV.

Provide EV/EBIT
for Qiagen NV.

Provide EV/OCF
for Qiagen NV.

Provide EV/FCFF
for Qiagen NV.

Provide EV/IC
for Qiagen NV.

Show me price targets
for Qiagen NV made by professional analysts.

What are the Revenue projections
for Qiagen NV?

How accurate were the past Revenue estimates
for Qiagen NV?

What are the Net Income projections
for Qiagen NV?

How accurate were the past Net Income estimates
for Qiagen NV?

What are the EPS projections
for Qiagen NV?

How accurate were the past EPS estimates
for Qiagen NV?

What are the EBIT projections
for Qiagen NV?

How accurate were the past EBIT estimates
for Qiagen NV?

Compare the revenue forecasts
for Qiagen NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Qiagen NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Qiagen NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Qiagen NV compared to its peers.

Compare the P/E ratios
of Qiagen NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Qiagen NV with its peers.

Analyze the financial leverage
of Qiagen NV compared to its main competitors.

Show all profitability ratios
for Qiagen NV.

Provide ROE
for Qiagen NV.

Provide ROA
for Qiagen NV.

Provide ROIC
for Qiagen NV.

Provide ROCE
for Qiagen NV.

Provide Gross Margin
for Qiagen NV.

Provide Operating Margin
for Qiagen NV.

Provide Net Margin
for Qiagen NV.

Provide FCF Margin
for Qiagen NV.

Show all solvency ratios
for Qiagen NV.

Provide D/E Ratio
for Qiagen NV.

Provide D/A Ratio
for Qiagen NV.

Provide Interest Coverage Ratio
for Qiagen NV.

Provide Altman Z-Score Ratio
for Qiagen NV.

Provide Quick Ratio
for Qiagen NV.

Provide Current Ratio
for Qiagen NV.

Provide Cash Ratio
for Qiagen NV.

What is the historical Revenue growth
over the last 5 years for Qiagen NV?

What is the historical Net Income growth
over the last 5 years for Qiagen NV?

What is the current Free Cash Flow
of Qiagen NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Qiagen NV.

Business Breakdown

Qiagen NV is a leading global provider of sample and assay technologies that empower researchers and healthcare professionals in their quest for answers in genomics and molecular biology. Founded in 1984 and headquartered in Hilden, Germany, the company has established a formidable presence in the biotechnology sector, offering innovative solutions that facilitate the detection of diseases, genetic research, and drug development. Qiagen’s diverse portfolio spans from nucleic acid extraction kits to molecular diagnostic tests, catering to both academic research institutions and clinical settings. This extensive product range not only supports the growing demand for precision medicine but also...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Qiagen NV

Current Assets 2.5B
Cash & Short-Term Investments 1.5B
Receivables 345.6m
Other Current Assets 628.1m
Non-Current Assets 3.8B
PP&E 759.9m
Intangibles 2.8B
Other Non-Current Assets 239.1m
Current Liabilities 1.1B
Accounts Payable 79m
Accrued Liabilities 494.3m
Other Current Liabilities 555.3m
Non-Current Liabilities 1.6B
Long-Term Debt 1.4B
Other Non-Current Liabilities 247.1m
Efficiency

Earnings Waterfall
Qiagen NV

Revenue
2B USD
Cost of Revenue
-732.8m USD
Gross Profit
1.2B USD
Operating Expenses
-769.9m USD
Operating Income
463.4m USD
Other Expenses
-370.5m USD
Net Income
92.9m USD

Free Cash Flow Analysis
Qiagen NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

QIAGEN reported a solid Q3 with $502 million in sales, exceeding its $495 million target, driven by a 10% growth in Diagnostic Solutions. Adjusted EPS increased to $0.57, surpassing the forecast of $0.55. The company anticipates 2024 net sales of at least $1.985 billion and has raised its adjusted EPS target to $2.19, up from $2.16, fueled by improved profitability and free cash flow, which surged 73% to $364 million. Product innovations, particularly in QIAstat and digital PCR, position QIAGEN for significant growth through 2028.

What is Earnings Call?
Fundamental Scores

QGEN Profitability Score
Profitability Due Diligence

Qiagen NV's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

56/100
Profitability
Score

Qiagen NV's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

QGEN Solvency Score
Solvency Due Diligence

Qiagen NV's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Low D/E
High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
64/100
Solvency
Score

Qiagen NV's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

QGEN Price Targets Summary
Qiagen NV

Wall Street analysts forecast QGEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for QGEN is 51.05 USD with a low forecast of 42.93 USD and a high forecast of 63 USD.

Lowest
Price Target
42.93 USD
0% Upside
Average
Price Target
51.05 USD
19% Upside
Highest
Price Target
63 USD
47% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for QGEN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for QGEN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

QGEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

QGEN News

Other Videos

Profile

Qiagen NV Logo
Qiagen NV

Country

Netherlands

Industry

Life Sciences Tools & Services

Market Cap

9.5B USD

Dividend Yield

3.09%

Description

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 6,028 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Contact

LIMBURG
Venlo
Hulsterweg 82
+31773556600.0
www.qiagen.com

IPO

1996-09-01

Employees

6 028

Officers

CEO, MD & Member of Management Board
Mr. Thierry Bernard
CFO, MD & Member of Management Board
Dr. Roland Sackers
Senior VP & Head of Global Operations
Mr. Antonio Santos
Vice President of Corporate Communications & Investor Relations
Mr. John Gilardi
Senior VP & Head of Human Resources
Ms. Stephany Foster
Senior Vice President of Life Science Business Area
Dr. Thomas Schweins
Show More
Senior Director & Head of External Communications
Dr. Thomas Theuringer
Senior VP & Head of Corporate Strategy and Business Development
Mr. Jean-Pascal Viola
Senior VP & Head of the QIAGEN Digital Insights Business Area
Dr. Jonathan G. Sheldon Ph.D.
Senior VP & Head of the Molecular Diagnostics Business Area
Mr. Fernando Beils
Show Less

See Also

Discover More
What is the Intrinsic Value of one QGEN stock?

The intrinsic value of one QGEN stock under the Base Case scenario is 40.9 USD.

Is QGEN stock undervalued or overvalued?

Compared to the current market price of 42.78 USD, Qiagen NV is Overvalued by 4%.

Back to Top